↓ Skip to main content

Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study

Overview of attention for article published in BMC Cancer, December 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
1 X user

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study
Published in
BMC Cancer, December 2021
DOI 10.1186/s12885-021-09050-6
Pubmed ID
Authors

Jin Zhang, Hongchuan Jiang, Jian Zhang, Guoqiang Bao, Guoqiang Zhang, Haibo Wang, Xi Wang

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 1 6%
Researcher 1 6%
Lecturer 1 6%
Student > Master 1 6%
Unknown 13 76%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 2 12%
Biochemistry, Genetics and Molecular Biology 1 6%
Unknown 14 82%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2022.
All research outputs
#3,338,746
of 23,577,654 outputs
Outputs from BMC Cancer
#803
of 8,530 outputs
Outputs of similar age
#82,211
of 513,575 outputs
Outputs of similar age from BMC Cancer
#20
of 223 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,530 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 513,575 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 223 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.